Who is sponsoring NCT00565370?

NCT00565370 is sponsored by Asan Medical Center.

What condition does NCT00565370 study?

NCT00565370 studies Advanced Gastric Cancer.

What drugs are being tested in NCT00565370?

Interventions: Capecitabine, Cisplatin, Sorafenib.

What is the status of NCT00565370?

NCT00565370 is currently COMPLETED.

Last reviewed 2020-01-06 · How we verify

A Phase I-II Study of Sorafenib (Nexavar®) in Combination With Capecitabine and Cisplatin (XP) in Patients With Advanced Gastric Cancer

NCT00565370 Phase 1/Phase 2 COMPLETED Results posted

There is strong scientific rationale for exploring the role of sorafenib with capecitabine and cisplatin (XP) in AGC. XP is a new standard of care in AGC and sorafenib is a novel signal transduction inhibitor that prevents tumor cell proliferation and angiogenesis through blockade of the Raf/MEK/ERK pathway at the level of Raf kinase and the receptor tyrosine kinases VEGF-R2 and PDGFR-beta.

Details

Lead sponsor	Asan Medical Center
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	22
Start date	2007-11
Completion	2009-12

Conditions

Advanced Gastric Cancer

Interventions

Capecitabine, Cisplatin, Sorafenib

Primary outcomes

Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 28weeks
Number of Participants who Experienced Dose Limiting Toxicities (DLTs)
Progression-free Survival — 1 year

Countries

South Korea